The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Updates on Giant Cell Arteritis

Updates on Giant Cell Arteritis

March 19, 2018 • By Susan Bernstein

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Patients with upper-extremity limb claudication may be younger than others with GCA, who have more typical cranial manifestations.9 Their diagnosis may be delayed because they lack the more common signs of GCA, said Dr. Kermani. “Maybe physicians don’t recognize it or think about it early enough. Inflammation may be in different segments, so they tend to have less vision loss,” she said. These GCA patients may have a negative temporal artery biopsy. “So if you suspect this diagnosis, large-vessel imaging is really the way to proceed in terms of your diagnostic evaluation.”

You Might Also Like
  • Diagnose, Manage and Treat Giant Cell Arteritis
  • Giant Cell Arteritis
  • Exciting Advances in Giant Cell Arteritis Diagnosis & Treatment
Explore This Issue
March 2018
Also By This Author
  • 2014 ACR/ARHP Annual Meeting: Medical Education Trends

Although GCA patients should be screened for aortic aneurysms, a late-stage complication, there is no consensus on the type of imaging modality or frequency and timing of screening in these patients, she said. GCA patients are also at increased risk for vertebrobasilar stroke, myocardial infarction and venous thromboembolism, so GCA screening may be considered in older patients who present with these vascular events.10

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Glucocorticoids have been the mainstay of GCA therapy in the past, and “prompt treatment in anyone with suspected GCA is essential to prevent vision loss. In patients where vision loss does occur, prompt institution of glucocorticoids can prevent contralateral eye involvement or progression of their visual deficit,” said Dr. Kermani. After a starting dose of 40–60 mg/day for one month, if symptoms resolve and biomarkers normalize, patients may taper their glucocorticoid dose. Patients with vision loss or ischemic complications such as limb claudication may need pulse steroids, she added. Aspirin is not routinely recommended.

Tocilizumab may help GCA patients lower their overall steroid dose and decrease relapse risk, according to the results of a Phase III, randomized clinical trial.11 Other potential therapies now in clinical trials include abatacept and ustekinumab, but these are not yet approved for GCA, she said.12,13

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Imaging Strengths & Limitations

Rheumatologists must select the right imaging modality at different points in the GCA disease process, said Peter C. Grayson, MD, MSc, Principal Investigator of the translational research program in vasculitis at the National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the National Institutes of Health (NIH). Ultrasound of extracranial vessels to diagnose GCA has many advantages, he said.14 It is relatively cheap, non-invasive, involves no radiation and can be performed at bedside.

“It’s a dynamic form of imaging. You can see how blood is flowing through the arteries and see signs of turbulence,” said Dr. Grayson. “The other thing you can see in ultrasound is the wall of the artery and the morphology of it. Is this imaging finding telling me that inflammation is going on in this vessel wall? What you will see, particularly in the cross-sectional view, is you can see this hypo-echoic rim around the lumen of the artery, which is what we call the halo sign. This tells me that there is likely this edematous, thickened arterial wall,” a sign of potential arteritis.

Pages: 1 2 3 4 5 6 | Single Page

Filed Under: Meeting Reports, Vasculitis Tagged With: ACR/ARHP Annual Meeting, giant cell arteritis (GCA)Issue: March 2018

You Might Also Like:
  • Diagnose, Manage and Treat Giant Cell Arteritis
  • Giant Cell Arteritis
  • Exciting Advances in Giant Cell Arteritis Diagnosis & Treatment
  • Varicella Zoster Virus May Cause Giant Cell Arteritis

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)